Intensive chemotherapy of diffuse large b-cell lymphosarcoma in a female patient with chronic renal failure and afunctional left kidney
- Authors: Egorova EK1, Mar'in DS1, Shutova NA1, Galstian GM1, Savenko TA1, Kremenetskaia AM1, Kravchenko SK1, Magomedova AU1, Kovalenko AV1, Kaplanskaia IB1, Samoĭlova RS1, Kliasova GA1, Kozlova SI.1
-
Affiliations:
- ГУ Гематологический научный центр РАМН, Москва
- Issue: Vol 80, No 7 (2008)
- Pages: 57-59
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30213
- ID: 30213
Cite item
Full Text
Full Text
##article.viewOnOriginalSite##About the authors
E K Egorova
ГУ Гематологический научный центр РАМН, Москва
D S Mar'in
ГУ Гематологический научный центр РАМН, Москва
N A Shutova
ГУ Гематологический научный центр РАМН, Москва
G M Galstian
ГУ Гематологический научный центр РАМН, Москва
T A Savenko
ГУ Гематологический научный центр РАМН, Москва
A M Kremenetskaia
ГУ Гематологический научный центр РАМН, Москва
S K Kravchenko
ГУ Гематологический научный центр РАМН, Москва
A U Magomedova
ГУ Гематологический научный центр РАМН, Москва
A V Kovalenko
ГУ Гематологический научный центр РАМН, Москва
I B Kaplanskaia
ГУ Гематологический научный центр РАМН, Москва
R S Samoĭlova
ГУ Гематологический научный центр РАМН, Москва
G A Kliasova
ГУ Гематологический научный центр РАМН, Москва
S Iu Kozlova
ГУ Гематологический научный центр РАМН, Москва
References
- Harris N. L., Jaffe Е. S., Diebold J. et al. World Health Organization classification diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee meeting. - Airline House, Virginia, November 1997. J. Clin. Oncol. 1999; 17 (12): 3835-3849.
- Harris N. L., Jaffe E. S., Stein H. et al. A revised European-American classification of lymphoid neoplasm's: A proposal from The International Lymphoma Study Group. Blood 1994; 84 (5): 1301-1392.
- Воробьев А. И. (ред.) Руководство по гематологии. М.: Ньюдиамед; 2003; т. 2: 55, 98-100.
- Бабичева Л. Г., Поддубная И. В. Дополнительные клинико-лабораторные факторы прогноза при диффузной В-крупноклеточной лимфоме. Соврем. онкол. 2006; 8(1): 37-41.
- Abramson J. S., Shipp M. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106 (4): 1164-1174.
- Alizadeh A. A., Elsen M. В., Davis R. E. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
- Barrans S., Carter I., Morgan G. J. et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99 (4): 1136-1142.
- Barrans S., Connor S., Evans P. et al. Rearrangement of the BCL-6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br. J. Haematol. 2002; 117: 322-332.
- Barrans S., Evans P., Connor S. et al. The t(14; 18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin. Cancer Res. 2003; 9: 2133-2139.
- Rosenwald A., Wright G., Chan W. C. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med. 2002; 346: 1937-1947.
- Shipp M. A., Ross K. N., Tramayo P. et al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat. Med. 2002; 8 (1): 68-74.
- Chung R., Lai R., Wei P. et al. Concordant but discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 2007; 110 (4): 1278-1282.
- Falini В., Fizzotti M., Pucciarini A. et al. A monoclonal antibody (MUM1) detects expression of the MUM1/IRF4 protein in a subset of germinal center В cells, plasma cells, and activated T cells. Blood 2000; 95: 2084-2092.
- ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N. Engl. J. Med. 2005; 353: 1197-1205.
- Balzarotti M., Spina M., Sarina B. et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann. Oncol. 2002; 13 (9): 1341-1346.
- Brusamolino E., Rusconi C., Montalbetti L. et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-502.
- Fisher R. Treatment of diffuse large B-cell lymphomas. Semin. Hematol. 2006; 34: 205.
- Coiffier В., Gisselbrecht C., Gaulard P. et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large-B-cell lymphoma. Blood 2003; 6 (6): 1182.
- Магомедова А. У., Кравченко С. К., Кременецкая А. М. и др. Модифицированная программа NHL-BFM-90 в лечении больных диффузной В-крупноклеточной лимфосаркомой. Тер. арх. 2006; 10: 44-47.
- Pfreundschuh М., Trumper L., Osterborg A. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol. 2006; 7: 379-391.
- Freytes C., Loberiza F., Rizzo D. et al. Myeloablative allogenic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104 (12): 3797-3803.
- Gisselbrecht C., Lepage E., Molina T. et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J. Clin. Oncol. 2002; 20 (10): 2472-2479.
![](/img/style/loading.gif)